Evidence supporting the use of: L-arginine
For the health condition: Congestive Heart Failure

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

L-arginine is an amino acid that serves as a precursor to nitric oxide, a molecule that helps dilate blood vessels and improve blood flow. The rationale for using L-arginine in congestive heart failure (CHF) stems from the observation that patients with CHF often have endothelial dysfunction and reduced nitric oxide production, which can worsen cardiac function. Several small clinical trials and experimental studies have explored the effects of L-arginine supplementation in heart failure patients. Some studies have reported improvements in hemodynamic parameters, such as increased exercise capacity and enhanced vasodilation, potentially leading to symptom relief in CHF. However, the overall quality and size of these studies are limited, and results have been inconsistent.

A notable randomized controlled trial (Rector et al., 1996) found that short-term L-arginine supplementation led to modest improvements in vascular function in CHF patients. Conversely, other research has failed to show significant clinical benefits or has raised concerns about potential adverse effects, including worsening outcomes in some cases. Major clinical guidelines do not currently recommend L-arginine supplementation as a standard treatment for CHF. The current evidence base is insufficient to support routine use, and more large-scale, well-controlled studies are needed to establish its efficacy and safety in this setting.

In summary, while there is some scientific rationale and preliminary clinical evidence for the use of L-arginine in CHF, the overall strength of evidence is weak, justifying a rating of 2 out of 5.

More about L-arginine
More about Congestive Heart Failure